Stem cell transparency
By Editorial,
Los Angeles Times
| 02. 20. 2006
AFTER A FIRST YEAR THAT veered off in too many bad directions, California's budding stem cell agency has started 2006 on more promising footing. At its meeting earlier this month, the governing board of the California Institute for Regenerative Medicine adopted admirable ethics standards and devised a fair formula for sharing future revenue.
The institute's ethics standards, which include requirements to inform potential egg donors of risks they face, are now higher than those recommended last year by the National Academy of Sciences. They should go a long way toward reassuring a public shaken by the scandal surrounding a South Korean stem cell researcher who faked many of his "breakthroughs" and coerced women into donating eggs.
see moreThe institute's rules for sharing future revenue from stem cell discoveries with the state fulfill a promise implicit in Proposition 71, the $3-billion bond measure to fund embryonic stem cell research. A few members of the governing board had balked at making provisions for the poor and uninsured to receive stem cell treatments made possible by California's investment. But the institute earlier this month...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...